Leukotriene A4

Leukotriene A4

0Leukotriene A4 (LTA4) is a leukotriene and an intermediate in the biosynthesis of other leukotrienes. It is produced by the enzyme 5-lipoxygenase from arachidonic acid in leukocytes. LTA4 is unstable and rapidly converted to other leukotrienes by various enzymes in the cells where it is produced.

Biosynthesis

Leukotrienes are a group of biologically active compounds derived from arachidonic acid. The biosynthesis of leukotrienes is initiated by the action of 5-lipoxygenase, an enzyme that catalyzes the conversion of arachidonic acid to 5-hydroperoxyeicosatetraenoic acid (5-HPETE) and then to LTA4. This reaction occurs in the presence of the 5-lipoxygenase-activating protein (FLAP), which facilitates the binding of arachidonic acid to 5-lipoxygenase.

Conversion to other leukotrienes

LTA4 is an unstable intermediate and is rapidly converted to other leukotrienes. The enzyme LTA4 hydrolase converts LTA4 to Leukotriene B4 (LTB4), a potent mediator of inflammation. Alternatively, LTA4 can be converted to Leukotriene C4 (LTC4) by the enzyme LTC4 synthase. LTC4 is the first of the cysteinyl leukotrienes, which also include Leukotriene D4 (LTD4) and Leukotriene E4 (LTE4).

Biological effects

The leukotrienes produced from LTA4 are involved in various physiological and pathological processes. LTB4 is a potent chemoattractant for leukocytes, contributing to the accumulation of these cells at sites of inflammation. The cysteinyl leukotrienes (LTC4, LTD4, and LTE4) are involved in bronchoconstriction, increased vascular permeability, and mucus secretion in the lungs, contributing to the symptoms of asthma.

Inhibition of leukotriene synthesis

The synthesis of leukotrienes can be inhibited by drugs that block the action of 5-lipoxygenase or FLAP, such as zileuton and MK-886, respectively. These drugs are used in the treatment of asthma and other inflammatory conditions.